Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1972 1
1973 2
1975 1
1977 1
1979 1
1981 1
1985 1
1996 2
1997 3
1998 2
2001 1
2002 1
2003 3
2005 2
2006 1
2007 1
2008 1
2009 2
2011 3
2012 4
2013 3
2014 1
2015 3
2016 3
2017 2
2018 4
2019 2
2020 4
2021 3
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. Among authors: auranen a. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Hormonal treatments and epithelial ovarian cancer risk.
Auranen A, Hietanen S, Salmi T, Grénman S. Auranen A, et al. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):692-700. doi: 10.1111/j.1525-1438.2005.00131.x. Int J Gynecol Cancer. 2005. PMID: 16174215 Free article. Review.
PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
Loukovaara M, Bützow R, Staff S, Mäenpää M, Faltinová M, Lassus H, Veijalainen O, Grönvall M, Vaalavirta L, Kuikka E, Haataja M, Urpilainen E, Simojoki M, Anttila M, Auranen A. Loukovaara M, et al. Among authors: auranen a. Int J Gynecol Cancer. 2023 Nov 6;33(11):1807-1811. doi: 10.1136/ijgc-2023-004939. Int J Gynecol Cancer. 2023. PMID: 37813479 Clinical Trial.
Decreasing trend and changing indications of hysterectomy in Finland.
Hakkarainen J, Nevala A, Tomás E, Nieminen K, Malila N, Pitkäniemi J, Auranen A. Hakkarainen J, et al. Among authors: auranen a. Acta Obstet Gynecol Scand. 2021 Sep;100(9):1722-1729. doi: 10.1111/aogs.14159. Epub 2021 May 4. Acta Obstet Gynecol Scand. 2021. PMID: 33797081 Free article.
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Barretina-Ginesta MP, Monk BJ, Han S, Pothuri B, Auranen A, Chase DM, Lorusso D, Anderson C, Abadie-Lacourtoisie S, Cloven N, Braicu EI, Amit A, Redondo A, Shah R, Kebede N, Hawkes C, Gupta D, Woodward T, O'Malley DM, González-Martín A. Barretina-Ginesta MP, et al. Among authors: auranen a. Ther Adv Med Oncol. 2022 Sep 22;14:17588359221126149. doi: 10.1177/17588359221126149. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36172173 Free PMC article.
64 results